METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC)
Clinical trials for METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Real-world study tracks prostate cancer treatment duration
Knowledge-focused CompletedThis study reviewed medical records from over 1,300 men with metastatic castration-sensitive prostate cancer to see how long they actually take the drugs apalutamide or enzalutamide. It is not a clinical trial but an observation of real-world treatment patterns. The goal is to un…
Matched conditions: METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC)
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated May 15, 2026 11:56 UTC
-
Finnish prostate cancer study reveals Real-World treatment patterns
Knowledge-focused CompletedThis study collected information from over 1,000 men in Finland with metastatic prostate cancer that has spread. Researchers looked at patient details, what treatments they received, and how well those treatments worked. The goal was to better understand the disease and its impac…
Matched conditions: METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC)
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC